Church & Dwight Webcasts Presentation at the 2025 Barclays Global Consumer Staples Conference
Church & Dwight Co., Inc. (NYSE: CHD) founded in 1846, is the leading U.S. producer of sodium bicarbonate, popularly known as baking soda. The Company manufactures and markets a wide range of personal care, household, and specialty products under recognized brand names such as ARM & HAMMER ®, TROJAN ®, OXICLEAN ®, FIRST RESPONSE ®, NAIR ®, ORAJEL ®, XTRA ®, L'IL CRITTERS ® and VITAFUSION ®, BATISTE ®, WATERPIK ®, ZICAM ®, THERABREATH ®, HERO ® and TOUCHLAND ®. For more information, visit the Company's website.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
28 minutes ago
- Business Wire
ExchangeRight Secures 50 Lease Renewals and Sustains 100% Rent Collection for its Essential Income REIT
PASADENA, Calif.--(BUSINESS WIRE)--ExchangeRight has announced that through Q2 2025 the company maintained 100% rent collections and executed 50 lease renewals across the company's entire net lease platform, including all properties in the Essential Income REIT. This strong asset management resulted in a net lease occupancy rate of 99.86% as of June 30, 2025, among the highest in the net lease sector. Through Q2 2025, ExchangeRight maintained 100% rent collections and executed 50 lease renewals across the company's entire net lease platform, including all properties in ExchangeRight's Essential Income REIT. Share ExchangeRight's Asset Management Update as of June 30, 2025 Leasing Performance Highlights (2023 – Q2 2025) 50 lease renewals executed with 11 national tenants operating essential businesses, including industry-leading retailers and service providers Average lease extension of 64 months, reinforcing long-term tenant commitments and supporting consistent cash flow to investors 6.15% weighted average rent increases secured on renewed leases, enhancing overall rental income and portfolio performance Net Lease Platform Occupancy 99.86% occupancy rate for ExchangeRight's net-leased assets under management as of June 30, 2025, reflecting one of the highest occupancy rates in the net lease sector 25:1 ratio of lease renewals and re-leases to vacancies, demonstrating strong tenant retention and successful re-leasing strategies Only 17 leases across the Net Lease Platform (0.60% of total platform rents) with expirations in the next 12 months, minimizing near-term rollover risk Past performance does not guarantee future results. 'Our disciplined Asset Management and Leasing teams continue to deliver strong results on behalf of investors, supporting ExchangeRight's reputation for proactive and investor-centric operational management,' said Tim Williams, director of asset management. 'These results benefit ExchangeRight's investors by supporting stable monthly distributions to empower investors to be secure, free, and generous.' 'As we execute our aggregation strategy and scale our REIT platform, each renewal strengthens long-term income potential for investors,' said Joshua Ungerecht, a managing partner at ExchangeRight. 'Our focus remains on stewarding investor capital faithfully by prioritizing operational excellence, creditworthy tenants, and recession-resilient assets throughout all market cycles.' About ExchangeRight ExchangeRight and its affiliates' vertically integrated platform features more than $6.6 billion in assets under management that are diversified across over 1,300 properties, and 26 million square feet throughout 47 states, as of July 31, 2025. ExchangeRight pursues its passion to empower people to be secure, free, and generous through its Essential Income REIT and 1031 DST portfolios that target secure capital, stable income, and strategic exits, all of which have historically met or exceeded investor projections since ExchangeRight's inception. On behalf of investors nationwide, the company structures and manages net-leased portfolios of assets backed primarily by investment-grade corporations that have successfully operated in the necessity-based retail and healthcare industries. Past performance does not guarantee future results. Please visit for more information.
Yahoo
43 minutes ago
- Yahoo
Viking Therapeutics stock falls 37% on high dropout rate in obesity trial
-- Viking Therapeutics (NASDAQ:VKTX) stock plunged as much as 37% Tuesday after revealing results from its Phase 2 VENTURE-Oral Dosing trial for its oral obesity treatment, while Eli Lilly (NYSE:LLY) shares gained 1.5% as analysts pointed to competitive advantages. The trial demonstrated that Viking's oral tablet formulation of VK2735, a dual GLP-1 and GIP receptor agonist, met its primary endpoint with patients losing up to 12.2% of body weight after 13 weeks compared to 1.3% for placebo. Despite the weight loss efficacy, the 28% treatment discontinuation rate among patients receiving VK2735 versus 18% for placebo raised significant concerns among investors and analysts. Mizuho analyst Jared Holz highlighted competitive disadvantages compared to Eli Lilly's offerings: "Data look inferior to LLY on almost all metrics and the thing to consider here is that patients discontinued at such a high rate over 13-weeks vs. LLY in the mid 20% range --- but over 72-weeks; A much longer trial, and therefor LLY looks far better head-to-head. This probably shutters hope for VKTX a bigtime player in the oral obesity market over the near to medium term." JPMorgan (NYSE:JPM) analyst Hardik Parikh offered a more balanced view, noting, "In 13 weeks, the three highest-dosing arms of 60/90/120mg showed avg pbo-adj weight loss of ~7.5%, 10%, 11%, which we think is very strong compared with other orals in development. Tolerability overall was manageable, but it was worse than we expected based on the ph1 performance." Parikh added that while the adverse event profile wasn't as clean as in Phase 1 trials, "we still think oral vk-2735 offers strong efficacy with a manageable tolerability profile." Viking reported that 99% of gastrointestinal-related adverse events were mild or moderate. The company also highlighted an exploratory maintenance dosing arm showing weight loss could be maintained at lower doses. The major adverse events included vomiting rates of 20-35% in the three highest dose arms compared to about 10% for placebo, and nausea rates of approximately 58% for patients on treatment versus 48% for placebo. Related articles Viking Therapeutics stock falls 37% on high dropout rate in obesity trial Tesla robotaxi trial impresses, pricing power clear: William Blair Palo Alto Networks gains after strong earnings and Bank of America upgrade
Yahoo
44 minutes ago
- Yahoo
Is Most-Watched Stock JD.com, Inc. (JD) Worth Betting on Now?
Inc. (JD) is one of the stocks most watched by visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Over the past month, shares of this company have returned -4.9%, compared to the Zacks S&P 500 composite's +2.5% change. During this period, the Zacks Internet - Commerce industry, which falls in, has gained 2.3%. The key question now is: What could be the stock's future direction? Although media reports or rumors about a significant change in a company's business prospects usually cause its stock to trend and lead to an immediate price change, there are always certain fundamental factors that ultimately drive the buy-and-hold decision. Revisions to Earnings Estimates Here at Zacks, we prioritize appraising the change in the projection of a company's future earnings over anything else. That's because we believe the present value of its future stream of earnings is what determines the fair value for its stock. Our analysis is essentially based on how sell-side analysts covering the stock are revising their earnings estimates to take the latest business trends into account. When earnings estimates for a company go up, the fair value for its stock goes up as well. And when a stock's fair value is higher than its current market price, investors tend to buy the stock, resulting in its price moving upward. Because of this, empirical studies indicate a strong correlation between trends in earnings estimate revisions and short-term stock price movements. is expected to post earnings of $0.40 per share for the current quarter, representing a year-over-year change of -67.7%. Over the last 30 days, the Zacks Consensus Estimate remained unchanged. For the current fiscal year, the consensus earnings estimate of $2.49 points to a change of -41.6% from the prior year. Over the last 30 days, this estimate has changed +0.3%. For the next fiscal year, the consensus earnings estimate of $3.61 indicates a change of +45.2% from what is expected to report a year ago. Over the past month, the estimate has changed +0.3%. With an impressive externally audited track record, our proprietary stock rating tool -- the Zacks Rank -- is a more conclusive indicator of a stock's near-term price performance, as it effectively harnesses the power of earnings estimate revisions. The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #5 (Strong Sell) for The chart below shows the evolution of the company's forward 12-month consensus EPS estimate: 12 Month EPS Revenue Growth Forecast Even though a company's earnings growth is arguably the best indicator of its financial health, nothing much happens if it cannot raise its revenues. It's almost impossible for a company to grow its earnings without growing its revenue for long periods. Therefore, knowing a company's potential revenue growth is crucial. In the case of the consensus sales estimate of $40.08 billion for the current quarter points to a year-over-year change of +8%. The $183.33 billion and $192.78 billion estimates for the current and next fiscal years indicate changes of +14% and +5.2%, respectively. Last Reported Results and Surprise History reported revenues of $49.79 billion in the last reported quarter, representing a year-over-year change of +24.2%. EPS of $0.69 for the same period compares with $1.29 a year ago. Compared to the Zacks Consensus Estimate of $46.93 billion, the reported revenues represent a surprise of +6.1%. The EPS surprise was +38%. The company beat consensus EPS estimates in each of the trailing four quarters. The company topped consensus revenue estimates each time over this period. Valuation No investment decision can be efficient without considering a stock's valuation. Whether a stock's current price rightly reflects the intrinsic value of the underlying business and the company's growth prospects is an essential determinant of its future price performance. While comparing the current values of a company's valuation multiples, such as price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), with its own historical values helps determine whether its stock is fairly valued, overvalued, or undervalued, comparing the company relative to its peers on these parameters gives a good sense of the reasonability of the stock's price. The Zacks Value Style Score (part of the Zacks Style Scores system), which pays close attention to both traditional and unconventional valuation metrics to grade stocks from A to F (an A is better than a B; a B is better than a C; and so on), is pretty helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued. is graded C on this front, indicating that it is trading at par with its peers. Click here to see the values of some of the valuation metrics that have driven this grade. Conclusion The facts discussed here and much other information on might help determine whether or not it's worthwhile paying attention to the market buzz about However, its Zacks Rank #5 does suggest that it may underperform the broader market in the near term. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Inc. (JD) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
